We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

3rd Circ. To Hear Class Cert. Appeal In Lamictal Case

Law360 (March 18, 2019, 6:10 PM EDT) -- The Third Circuit on Monday agreed to hear an appeal from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. as they look to nix a class certification for buyers accusing the drugmakers of delaying generic alternatives to the mood stabilizer Lamictal.

An appellate panel granted a petition from GSK and Teva seeking permission to appeal a December ruling in New Jersey district court that certified a class of direct purchasers who allegedly overpaid for the branded version of the drug or its generic. Last month U.S. Magistrate Judge Cathy L. Waldor stayed the sending of class notices until the circuit court could...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS